OakChart

GRAIL Inc

GRALHealthcare·Diagnostics & Research·USA·Mid·NASD·Nov 11 • 10:37 AM ET

128.09+3.35 (2.69%)
2026-11-11 16:38 CET
Market cap
5,608.58 USD m
Revenue, TTM
166.60 USD m
Net income, TTM
-406.18 USD m
Free cash flow, TTM
-312.00 USD m
EPS diluted, TTM
-9.50
P/E
-
Compare

Price

GRAL against its 20, 50 and 200-day averages
2050200beat
50.00100.00150.001.8M3.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GRALclose 128.0920-day 134.0850-day 119.38200-day 79.09128.0952w high

23.1% under the 52-week high of 166.48 on 6 Oct 2026. 52-week low 41.50 on 23 Feb 2026. Last 15 sessions, 38.4% high to low

Profile

GRAL
52-week range, 69% of the way up
41.50166.48

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

IndexRUT
Employees910
IPOJun 12, 2024
Beta2.99
ATR, 14d11.71
Rel volume0.28
Short float18.85%
Insider own5.62%
Inst own86.22%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap5.76B
Enterprise Value5.06B
Income-406.18M
Sales166.60M
Book/sh54.82
Cash/sh17.54
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees910
IPOJun 12, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S34.57
P/B2.34
P/C7.30
P/FCF-
EV/EBITDA-
EV/Sales30.35
Quick Ratio8.74
Current Ratio8.93
Debt/Eq0.03
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-9.50
EPS next Y-9.85
EPS next Q-2.38
EPS this Y13.76%
EPS next Y-2.77%
EPS next 5Y3.82%
EPS past 3/5Y60.02% -41.05%
Sales past 3/5Y38.37% -
EPS Y/Y TTM18.16%
Sales Y/Y TTM17.47%
EPS Q/Q10.11%
Sales Q/Q3.71%
EarningsNov 04 AMC
EPS/Sales Surpr.13.52% -15.09%

Ownership

Insider Own5.62%
Insider Trans-4.94%
Inst Own86.22%
Inst Trans5.02%
ROA-15.24%
ROE-17.31%
ROIC-16.03%
Gross Margin-37.82%
Oper. Margin-332.02%
Profit Margin-243.80%
SMA20-4.47%
SMA507.29%
SMA20061.95%
Trades-

Technical

Shs Outstand44.75M
Shs Float42.44M
Short Float18.85%
Short Ratio7.59
Short Interest8.00M
52W High166.48 -23.06%
52W Low41.50 208.65%
Volatility9.30% 8.38%
ATR (14)11.71
RSI (14)48.79
Beta2.99
Rel Volume0.28
Avg Volume1.05M
Volume63,282

Performance

Perf Week-10.84%
Perf Month-8.74%
Perf Quarter87.71%
Perf Half Y111.82%
Perf YTD49.66%
Perf Year53.60%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom2.33
Target Price139.44
Prev Close124.74
Price128.09
Change %2.69%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Sep 17, 2026InitiatedRRBC Capital MktsSector Perform$84-34.4%
Sep 09, 2026ResumedUUBSBuy$105-18.0%
Jun 05, 2026InitiatedGGoldmanNeutral$60-53.2%
Jun 02, 2026ResumedWWolfe ResearchPeer Perform
Apr 10, 2026InitiatedMMizuhoNeutral$58-54.7%
Mar 18, 2026UpgradeTTD CowenHold → Buy$65-49.3%
Feb 19, 2026InitiatedTTD CowenHold$114-11.0%
Feb 17, 2026InitiatedRRobert W. BairdOutperform$113-11.8%
Dec 02, 2025ResumedMMorgan StanleyEqual-Weight$110-14.1%
Nov 12, 2025UpgradeGGuggenheimNeutral → Buy$100-21.9%

Peers

Mkt cap
TickerCompanyMkt cap
GHGuardant Health Inc21.52B
FRNMFreenome Inc1.19B
NTRANatera Inc46.46B
BLLNBilliontoone Inc5.31B
ILMNIllumina Inc32.92B
NEONeogenomics Inc2.22B
VCYTVeracyte Inc2.03B
DGXQuest Diagnostics Inc28.50B
TEMTempus AI Inc14.86B
CAICaris Life Sciences Inc7.21B

Insider trading

latest 14 of 46
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ofman Joshua J.Chief Executive OfficerOct 15 '26Sale136.8520,0002,736,945342,271Oct 16 04:50 PM
JOSHUA OFMANDirectorOct 15 '26Proposed Sale139.705,000698,500Oct 15 04:41 PM
Partridge Andrew JohnChief Growth OfficerOct 05 '26Sale146.397,8731,152,528155,865Oct 07 06:36 PM
Freidin AaronChief Financial OfficerOct 05 '26Sale146.3923,6193,457,585225,364Oct 07 06:36 PM
Andrew PartridgeOfficerOct 05 '26Proposed Sale146.397,8731,152,533Oct 05 07:53 PM
Aaron FreidinOfficerOct 05 '26Proposed Sale146.3923,6193,457,600Oct 05 07:52 PM
Freidin AaronChief Financial OfficerSep 21 '26Sale93.344,100382,679248,983Sep 23 04:37 PM
Ofman Joshua J.Chief Executive OfficerSep 21 '26Option Exercise14.0026,452370,328423,723Sep 23 04:37 PM
Ofman Joshua J.Chief Executive OfficerSep 21 '26Sale97.7461,4526,006,378362,271Sep 23 04:37 PM
JOSHUA OFMANDirectorSep 21 '26Proposed Sale80.7771,4525,771,178Sep 21 04:34 PM
Ofman Joshua J.Chief Executive OfficerAug 27 '26Sale85.025,000425,098397,271Aug 31 08:07 PM
Freidin AaronChief Financial OfficerAug 27 '26Sale85.017,900671,579253,083Aug 31 08:07 PM
JOSHUA OFMANDirectorAug 27 '26Proposed Sale79.5910,000795,900Aug 27 04:26 PM
AARON FREIDINOfficerAug 27 '26Proposed Sale79.5912,000955,080Aug 27 04:18 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFACU.S. Core Equity 2 Portfolio-ETF Class Shares-

News

latest 14 of 206
  • It Was Already A Gory Day For Blood-Testing Stocks - Then, Natera And Guardant Reported (Investor's Business Daily) -17.08%
  • GRAIL Beats On EPS, But Guidance Cut, Price Concessions And Margin Compression Undercut A De-Risked FDA Story (Earnings Whispers)
  • Grail tumbles as revenue misses estimates despite FDA vote (Investing.com)
  • Grail Comes Up Short, Reporting Light Sales Of Its Cancer-Detecting Blood Test (Investor's Business Daily)
  • GRAIL Reports Third Quarter 2026 Financial Results (PR Newswire)
  • Loading…
  • GRAIL's Doubled Stock Faces A Test Of Volume Growth, Pricing And FDA Timing (Earnings Whispers) +7.65%
  • GRAIL to Present at the UBS Global Healthcare Conference (PR Newswire)
  • IBD Stock Of The Day, Natera, Hovering Near Buy Point (Investor's Business Daily)
  • 7 healthcare stocks that stand out as investors pay up for the sector (MarketWatch) +6.36%
  • GRAIL to Announce Third Quarter 2026 Financial Results (PR Newswire)
  • GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 (PR Newswire) +7.55% -10.90%
  • A Cancer Test Has Investors Betting Big. But Will Insurers Pay? (The Wall Street Journal) -5.40%
  • Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next. (Investor's Business Daily)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-2.210-2.556-2.21037.5444.218
2026Q22026-08-05-2.560-2.656-2.55744.6942.399
2026Q12026-05-05-2.290-2.763-2.29340.7939.167
2025Q42026-02-19-2.440-2.700-2.43543.6043.585
2025Q32025-11-12-2.460-3.365-2.46336.1934.604
2025Q22025-08-12-3.180-3.568-3.18535.5436.904
2025Q12025-05-13-3.100-3.987-3.09631.8435.203
2024Q42025-02-20-2.890-4.973-2.86438.2534.403
2024Q32024-11-12-3.940-6.430-3.78528.6533.901
2024Q22024-08-28-51.050--51.05932.00--
2026Q4---2.383--45.588
2027Q1---2.438--45.788
2027Q2---2.425--52.958
2027Q3---2.449--49.628
2027Q4---2.577--64.607
2028Q1---2.160--57.961

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-63.540-51.263-59.805125.6122.26
2025FY-11.110-11.410-11.110147.17146.94
2026FY--9.581--169.03
2027FY--9.846--211.31
2028FY--9.884--276.19
2029FY--9.585--371
2030FY--8.573--490.53

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06100945.5843.5848.33
2026Q4S2026-11-05100647.3243.5851.52
2026Q4S2026-11-04100051.1648.3354.03
2026Q4S2026-10-21100051.1648.3354.03
2026Q4S2026-10-20101051.1648.3354.03
2026Q4S2026-10-16103351.1648.3354.03
2026Q4S2026-10-12103351.1648.3054.03
2026Q4S2026-09-23103351.1648.3054.00
2026Q4S2026-09-18103351.1648.3354.00
2026Q4S2026-09-16103351.1648.3054.00
2026Q4S2026-09-0893351.2548.3054.00
2026Q4S2026-08-1283351.2148.3054.00
2026Q4S2026-08-0783451.2148.3054.00
2026Q4S2026-08-0682450.9247.3854.00

Estimate history

EPS, annual-2.42-40.183-173.869-47.2-59.805-11.111-9.4994
Period201820212022202320242025TTM
EPS, quarterly-3.785-2.864-3.096-3.185-2.463-2.435-2.293-2.557-2.214
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual014.61255.5593.105125.595147.172166.6
Period201820212022202320242025TTM
Sales, quarterly28.65238.25231.83735.54436.19443.59740.78544.68737.535
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual130.36231.05331.05331.05333.89340.33144.753
Period201820212022202320242025MRQ
Shares, quarterly33.20433.89335.29736.04836.16140.33141.13444.66644.753
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2018FY
Total Revenue166.60147.17125.5993.1155.5514.61-0.00
Cost of Goods Sold Incl. D&A229.61224.54203.62188.72172.00114.61-14.08
Gross Profit-63.01-77.36-78.02-95.61-116.45-100.00--14.08
Selling, General and Administrative Excl. Other490.15456.83649.73701.30626.011,165.34-267.72
Research and Development183.98185.38313.30338.75329.58460.21-203.38
Other Operating Expense0.000.000.000.000.000.00-0.00
Operating Income-553.15-534.20-727.75-796.92-742.46-1,265.34--281.80
Interest Expense0.000.000.000.000.000.00--
Unusual Expense25.4227.971,461.41718.474,700.430.00-5.70
Net Income Before Taxes-548.07-534.50-2,162.36-1,507.64-5,441.39-1,265.25--275.23
Income Taxes-141.89-126.15-135.36-41.95-42.29-17.48-0.48
Consolidated Net Income-406.18-408.35-2,027.01-1,465.68-5,399.10-1,247.78--275.72
Net Income From Continuing Operations-406.18-408.35-2,027.01-1,465.68-5,399.10-1,247.78--275.72
Net Income-406.18-408.35-2,027.01-1,465.68-5,399.10-1,247.78--275.72
EPS (Recurring)-8.30-10.58-29.62-31.00-67.91-40.18--2.38
EPS (Basic, Before Extraordinaries)-9.50-11.11-59.81-47.20-173.87-40.18--2.42
EPS (Diluted)-9.50-11.11-59.81-47.20-173.87-40.18--2.42
EBITDA-398.29-377.85-569.70-638.22-587.70-1,206.89--267.72
Non-Operating Income (Expense)30.5127.6626.807.751.500.09-12.26
Other After Tax Adjustments0.000.000.000.000.000.00-0.00
Stock Option Compensation Expense45.8544.5865.1973.7857.68518.79-8.06
Price To Sales Ratio39.3421.374.82-----
Gross Margin-37.82-52.57-62.12-102.69-209.63-684.39--
Operating Margin-332.02-362.97-579.44-855.93-1,336.56-8,659.61--
Net Margin-243.80-277.47-1,613.92-1,574.23-9,719.35-8,539.39--
Shares Outstanding44.7540.3333.8931.0531.0531.05-130.36
Market Capitalization5,608.585,608.58599.77626.32----

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue37.5344.6940.7843.6036.1935.5431.8438.25
Cost of Goods Sold Incl. D&A56.7658.3656.2058.2953.5357.9155.3754.22
Gross Profit-19.22-13.68-15.42-14.69-17.34-22.37-23.54-15.97
Selling, General and Administrative Excl. Other125.40134.68120.35109.72107.95108.49130.11121.66
Research and Development44.0747.4348.0244.4546.1546.6351.0748.96
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-144.62-148.36-135.76-124.41-125.29-130.85-153.64-137.63
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.0025.420.000.000.0028.00-0.03-0.69
Net Income Before Taxes-137.32-166.71-127.52-116.52-118.72-152.86-146.41-126.99
Income Taxes-33.75-56.46-34.34-17.34-29.74-38.87-40.20-29.93
Consolidated Net Income-103.57-110.25-93.19-99.18-88.98-113.98-106.21-97.07
Net Income From Continuing Operations-103.57-110.25-93.19-99.18-88.98-113.98-106.21-97.07
Net Income-103.57-110.25-93.19-99.18-88.98-113.98-106.21-97.07
EPS (Recurring)-2.21-2.14-2.29-2.44-2.46-2.64-3.10-2.88
EPS (Basic, Before Extraordinaries)-2.21-2.56-2.29-2.44-2.46-3.18-3.10-2.86
EPS (Diluted)-2.21-2.56-2.29-2.44-2.46-3.18-3.10-2.86
EBITDA-106.14-109.67-96.97-85.50-86.31-92.79-114.36-98.19
Non-Operating Income (Expense)7.307.088.247.896.576.007.209.94
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.1515.4513.275.9913.5013.2711.8210.29
Price To Sales Ratio39.3417.8113.4523.6815.0613.716.704.82
Gross Margin-51.21-30.61-37.81-33.70-47.91-62.93-73.92-41.74
Operating Margin-385.29-332.00-332.88-285.37-346.17-368.15-482.59-359.80
Net Margin-275.92-246.71-228.48-227.48-245.83-320.69-333.61-253.75
Shares Outstanding44.7544.6741.1340.3336.1636.0535.3033.89
Market Capitalization5,608.582,929.922,119.933,336.492,131.511,849.76865.68599.77

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2018FY
Cash & Short Term Investments904.43763.4797.29241.60--641.35
Short Term Receivables18.3024.6422.3518.61--0.00
Inventories16.0218.6321.7019.75--0.00
Other Current Assets15.1113.1214.7315.67--7.88
Total Current Assets953.85819.86156.06295.63--649.23
Net Property, Plant & Equipment103.88135.43169.38198.72--33.04
Total Investments and Advances6.973.354.224.53--1.63
Intangible Assets1,850.562,016.893,576.164,432.96---
Deferred Tax Assets256.09159.09643.11664.12---
Other Assets6.757.777.986.14--2.94
Total Assets3,178.103,142.404,556.935,602.10--686.85
Short Term Debt Incl. Current Port. of LT Debt11.7113.2614.8113.34--0.00
Accounts Payable2.084.8419.6717.48--12.75
Other Current Liabilities65.8758.82129.13104.12--61.41
Total Current Liabilities79.6776.92163.61134.94--74.16
Long Term Debt43.1554.8869.6082.67--0.80
Provision for Risks Charges0.000.000.000.00--0.00
Deferred Tax Liabilities474.67504.95676.03735.19---
Other Liabilities2.752.241.503.13--11.52
Total Liabilities600.24638.99910.74955.94--86.47
Non-Equity Reserves0.000.000.000.00--0.00
Preferred Stock - Carrying Value0.000.000.000.00--1,603.22
Common Equity2,577.862,503.413,646.194,646.16---1,002.85
Total Shareholders Equity2,577.862,503.413,646.194,646.16--600.37
Accumulated Minority Interest0.000.000.000.00--0.00
Total Equity2,577.862,503.413,646.194,646.16--600.37
Total Liabilities & Stockholders Equity3,178.103,142.404,556.935,602.10--686.85
Book Value Per Share63.9273.86117.42149.62---7.69
Tangible Book Value Per Share18.0314.352.266.87---7.69
Full-Time Employees9101,0001,3401,279---
Price to Book Ratio2.280.230.24----
Return on Assets-12.92-52.65-28.85----
Return on Equity-16.07-65.92-35.35----
Return on Invested Capital-15.58-79.23-39.44-114.17---45.86
Quick Ratio11.7710.420.822.04--8.75
Current Ratio11.9710.660.952.19--8.75

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2018FY
Net Income-406.18-408.35-2,027.01-1,465.68-5,399.10-1,247.78--275.72
Depreciation154.87156.34158.06158.70154.7658.45-14.08
Other Funds (Non Cash)67.6766.751,450.32741.624,736.55497.09-12.70
Funds from Operations-326.17-311.42-552.88-603.52-546.85-709.72--248.94
Extraordinary Item0.000.000.000.000.000.00-0.00
Changes in Working Capital19.9212.41-24.287.72-14.4621.59-39.67
Cash from Operating Activities-306.24-299.01-577.16-595.80-561.31-688.13--209.26
Capital Expenditures-5.76-0.91-5.21-12.89-22.86-69.93--15.99
Net Assets From Acquisitions0.000.000.000.000.000.00-0.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00-0.48
Purchase or Sale of Investments-323.28-84.14-545.800.000.00414.74--77.88
Purchase of Investments-1,657.88-1,308.34-545.800.000.00-159.41--681.13
Sale Or Maturity of Investments1,334.601,224.200.000.000.00574.15-603.25
Other Uses0.000.000.000.000.000.00-0.00
Other Sources0.000.000.000.000.000.00-0.00
Cash from Investing Activities-329.04-85.05-551.01-12.89-22.86344.81--93.39
Cash Dividends Paid0.000.000.000.000.000.00-0.00
Change in Capital Stock537.30423.320.000.000.005.81-302.13
Repurchase of Common Pref Stock0.000.000.000.000.00-0.17--0.28
Sale of Common Pref Stock537.30423.320.000.000.005.98-302.41
Proceedsfrom Stock Options225.98112.000.000.000.000.00-299.56
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00--1.51
Change in Long Term Debt0.000.000.000.000.000.00--1.51
Issuance of Long Term Debt0.000.000.000.000.000.00-0.00
Reduction of Long Term Debt0.000.000.000.000.000.00--1.51
Net Financing Active Other Cash Flow0.000.001,244.30463.77604.82388.93-0.00
Other Financing Activities Uses0.000.000.00-0.23-4.18-630.07-0.00
Cash from Financing Activities537.30423.321,244.30463.77604.82394.74-300.62
Exchange Rate Effect0.03-0.15-0.060.30-0.51-0.20-0.48
Net Change in Cash-97.9539.12116.07-144.6220.1351.23--1.55
Free Cash Flow-312.00-299.92-582.36-608.69-584.17-758.06--225.25
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit--126.15-134.25-38.15-39.06-17.48-0.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments788.68861.61823.11904.43540.13602.75
Short Term Receivables19.0019.7620.3418.3016.2816.31
Inventories18.4817.7617.1916.0218.3919.74
Other Current Assets16.6515.5916.7015.1114.5813.04
Total Current Assets842.80914.72877.35953.85589.38651.84
Net Property, Plant & Equipment126.76133.2595.91103.88112.24120.24
Total Investments and Advances6.946.976.976.976.973.35
Intangible Assets1,746.811,781.391,815.971,850.561,885.141,919.72
Deferred Tax Assets---256.09--
Other Assets7.257.357.276.757.297.39
Total Assets2,730.562,843.692,803.473,178.102,601.032,702.55
Short Term Debt Incl. Current Port. of LT Debt6.2710.709.9411.7114.0213.69
Accounts Payable10.217.244.672.083.416.28
Other Current Liabilities77.8565.6060.1065.8760.0050.67
Total Current Liabilities94.3383.5474.7179.6777.4370.64
Long Term Debt79.5880.6141.0943.1544.5748.48
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities99.74133.71184.03474.67236.26266.17
Other Liabilities3.393.172.952.752.802.62
Total Liabilities277.04301.03302.79600.24361.07387.91
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity2,453.522,542.652,500.692,577.862,239.962,314.64
Total Shareholders Equity2,453.522,542.652,500.692,577.862,239.962,314.64
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity2,453.522,542.652,500.692,577.862,239.962,314.64
Total Liabilities & Stockholders Equity2,730.562,843.692,803.473,178.102,601.032,702.55
Book Value Per Share54.8256.9360.7963.9261.9464.21
Tangible Book Value Per Share15.7917.0416.6518.039.8110.96
Full-Time Employees---910--
Price to Book Ratio2.281.120.811.380.920.75
Return on Assets-15.24-14.12-13.99-12.92-14.21-14.83
Return on Equity-17.31-16.12-16.09-16.07-16.83-17.68
Return on Invested Capital-4.09-4.20-3.67-3.78-3.89-4.82
Quick Ratio8.7410.7411.5111.777.378.95
Current Ratio8.9310.9511.7411.977.619.23

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-103.57-110.25-93.19-99.18-88.98-113.98
Depreciation38.4838.6938.7938.9138.9839.17
Other Funds (Non Cash)9.3639.2810.098.959.7337.48
Funds from Operations-89.70-88.95-78.85-68.67-70.01-76.20
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital14.968.22-8.144.886.76-0.77
Cash from Operating Activities-74.74-80.73-86.99-63.78-63.24-76.97
Capital Expenditures-4.73-0.43-0.50-0.09-0.38-0.37
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments52.41-46.14-92.94-236.6167.0670.74
Purchase of Investments-291.19-462.44-337.83-566.41-239.44-281.96
Sale Or Maturity of Investments343.60416.30244.90329.80306.50352.70
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities47.68-46.58-93.44-236.7066.6770.37
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.37113.610.00423.320.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.37113.610.00423.320.000.00
Proceedsfrom Stock Options0.37113.610.00112.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.37113.610.00423.320.000.00
Exchange Rate Effect-0.01-0.000.040.00-0.340.13
Net Change in Cash-26.70-13.70-180.38122.833.09-6.47
Free Cash Flow-79.47-81.16-87.49-63.88-63.63-77.33

Revenue breakdown

Developmental Services2024: 16.97M 2025: 8.57M
Screening2024: 108.63M 2025: 138.60M
Non-US2024: 14.78M 2025: 10.08M
United States2024: 110.82M 2025: 137.09M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.85%8.0M42.4M1.05M
2026-10-1519.39%8.2M42.2M970.09K
2026-09-3019.07%8.0M42.0M883.81K
2026-09-1520.41%8.6M42.0M652.23K
2026-08-3120.29%8.5M42.0M701.15K
2026-08-1419.94%8.2M40.9M703.53K
2026-07-3118.32%7.5M40.9M669.92K
2026-07-1519.68%7.7M39.3M678.73K
2026-06-3019.73%7.8M39.3M758.28K
2026-06-1518.01%7.1M39.5M771.64K
2026-05-2916.18%6.4M39.3M801.76K
2026-05-1518.36%7.2M38.9M1.23M
2026-04-3017.93%7.0M38.9M1.24M
2026-04-1518.78%7.0M37.2M1.33M
2026-03-3119.43%7.2M36.9M1.29M
2026-03-1317.73%6.5M36.9M1.28M
2026-02-2717.98%6.3M35.0M1.23M
2026-02-1315.60%5.5M35.0M905.34K
2026-01-3014.96%5.1M34.0M962.81K
2026-01-1515.79%5.4M34.0M1.03M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call40.0086.1090.700.005.0460.000.000.997-0.0300.002
call45.0081.1085.600.004.5720.000.000.983-0.1750.009
call50.0076.1080.7070.004.1530.000.000.981-0.1740.009
call55.0071.1075.700.003.7770.000.000.979-0.1720.010
call60.0066.2070.700.003.4360.000.000.977-0.1710.011
call65.0061.2065.700.003.1220.000.000.974-0.1690.012
call70.0056.2060.700.002.8750.000.000.972-0.1670.013
call75.0051.3055.8040.152.6019.000.000.969-0.1640.014
call80.0046.3050.7055.802.37926.000.000.954-0.2190.020
call85.0041.4045.9050.002.16615.000.000.948-0.2140.021
call90.0036.6040.8030.901.95837.000.000.942-0.2080.023
call95.0031.7035.9025.481.78222.000.000.920-0.2550.030
call10027.0031.0043.651.58069.000.000.908-0.2440.033
call10522.3025.8022.971.4019.000.000.880-0.2690.040
call11017.7021.0015.871.23523.000.000.828-0.3310.052
call11513.5017.0011.001.17039.000.000.759-0.3960.063
call1209.8013.307.661.10558.000.000.682-0.4370.072
call1258.0010.008.901.11176.001.000.592-0.4800.078
call1304.307.505.501.03411642.000.498-0.4670.081
call1353.006.002.731.1201780.000.408-0.4830.078
call1401.954.703.491.1521703.000.337-0.4700.073
call1451.203.802.771.1741251.000.283-0.4450.068
call1500.001.751.791.1543821.000.214-0.3760.059
call1550.101.701.341.10352.000.000.157-0.2970.049
call1600.201.150.871.0931620.000.115-0.2370.039
call1650.051.300.551.2142521.000.106-0.2480.037
call1700.050.800.401.1902071.000.079-0.1960.030
call1750.000.700.301.25960.001.000.068-0.1840.026
call1800.000.650.351.3291420.000.065-0.1880.026
call1850.050.650.351.40328.001.000.058-0.1820.023
call1900.050.600.201.44337.000.000.053-0.1740.022
call1950.002.351.401.53111.000.000.051-0.1780.021
call2000.100.550.101.5761494.000.046-0.1690.019
call2100.052.300.051.70910.000.000.043-0.1740.018
call2200.002.252.001.8293.000.000.041-0.1780.018
call2300.002.251.001.9653.000.000.042-0.1940.018
call2400.000.701.002.12573.000.000.044-0.2080.019
put40.000.000.050.052.70788.000.00-0.003-0.0230.002
put45.000.002.151.753.6113.000.00-0.017-0.1700.009
put50.000.002.151.013.2670.000.00-0.019-0.1680.009
put55.000.002.151.202.9717.000.00-0.021-0.1660.010
put60.000.002.150.052.69410.000.00-0.023-0.1640.011
put65.000.002.151.052.4405.000.00-0.026-0.1610.012
put70.000.002.150.182.20419.000.00-0.028-0.1580.013
put75.000.100.550.151.84649.000.00-0.033-0.1420.015
put80.000.051.600.301.94598.000.00-0.047-0.2090.020
put85.000.002.250.201.73286.000.00-0.052-0.2040.021
put90.000.000.850.251.5317890.00-0.059-0.1970.023
put95.000.202.401.701.4781480.00-0.080-0.2440.030
put1000.001.201.001.2801820.00-0.092-0.2330.033
put1050.501.602.681.16680.000.00-0.120-0.2570.040
put1100.652.302.401.13364.000.00-0.172-0.3190.052
put1150.653.503.701.09432.000.00-0.246-0.3780.063
put1202.204.903.481.0743552.00-0.318-0.4230.072
put1254.307.104.731.0824273.00-0.408-0.4660.078
put1307.009.408.301.04436910.00-0.502-0.4530.081
put1359.6013.0016.001.12630.000.00-0.584-0.4670.079
put14013.4016.5013.221.1901800.00-0.658-0.4490.074
put14517.4020.6025.801.2312230.00-0.717-0.4290.068
put15021.9025.0027.001.31579.000.00-0.825-0.2680.052
put15526.4029.5021.801.37812.000.00-0.843-0.2800.049
put16031.2034.4023.421.4925.000.00-0.885-0.2200.039
put16536.0039.3024.601.5971.000.00-0.893-0.2290.037
put17041.0044.0022.001.65627.000.00-0.921-0.1780.030
put17545.9049.0047.801.76438.000.00-0.932-0.1640.027
put18050.9054.0029.001.8672.000.00-0.935-0.1680.026
put18555.8059.0036.481.9651.000.00-0.941-0.1610.024
put19060.8064.0062.602.0591.000.00-0.947-0.1530.022
put19565.8069.0067.602.1491.000.00-0.949-0.1560.021
put20070.8074.000.002.2360.000.00-0.954-0.1470.020
put21080.8084.000.002.4000.000.00-0.957-0.1500.019
put22089.9094.000.002.5770.000.00-0.959-0.1540.018
put23099.70103.90.002.7220.000.00-0.961-0.1560.017
put240109.4113.995.102.8580.000.00-0.963-0.1590.016

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-27144Filing for proposed sale of securities under Rule 144.SEC
2026-08-27144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-06SCHEDULE 13G/ASEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10007.35M3
2026-09006.39M2
2026-08001.10M2
2026-070000
2026-060091.07K1
2026-050000
2026-040011.53M3
2026-03003.96M9
2026-020000
2026-010000
2025-12007.59M3
2025-110079.98M2

Institutional holders

Manager% owned
FARALLON CAPITAL MANAGEMENT, L.L.C.9.70%
BAKER BROS. ADVISORS LP9.39%
BlackRock, Inc.8.33%
Arbiter Partners Capital Management LLC7.23%
STATE STREET CORP5.56%
PRIMECAP MANAGEMENT CO/CA/5.08%
Sessa Capital IM, L.P.4.75%
Deep Track Capital, LP4.28%
VANGUARD CAPITAL MANAGEMENT LLC3.82%
MORGAN STANLEY3.41%

Funds

Fund% owned
PRIMECAP Odyssey Aggressive Growth Fund3.68%
State Street(R) SPDR(R) S&P(R) Biotech ETF3.32%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.86%
iShares Russell 2000 ETF2.51%
Fidelity Small Cap Index Fund1.05%
iShares Russell 2000 Value ETF0.90%
VANGUARD EXTENDED MARKET INDEX FUND0.87%
iShares Biotechnology ETF0.65%
VANGUARD RUSSELL 2000 INDEX FUND0.53%
VANGUARD CAPITAL OPPORTUNITY FUND0.38%

OakChart. GRAL. Cached 15 minutes.